More about

Inflammation

News
January 14, 2020
2 min read
Save

More research needed as interest in biologics grows

KOLOA, Hawaii — As interest in orthobiologics continues to grow, Matthew T. Provencher, MD, noted in a Facebook Live event hosted at Orthopedics Today Hawaii that orthopedists need to be cognizant of the exact definition of orthobiologics and where it fits within the specialty.

News
January 07, 2020
1 min read
Save

Enrollment to test NASH drug candidate complete

Akero Therapeutics announced that it has completed enrollment for a phase 2a study of AKR-001, the company’s FGF21 analog candidate for the treatment of nonalcoholic steatohepatitis, according to a press release.

News
December 05, 2019
3 min read
Save

Is there any truth to the idea of ‘no rub, no cone?’

Is there any truth to the idea of ‘no rub, no cone?’

The “no rub, no cone” theory states that excessive eye rubbing is a necessary ingredient in the genesis of keratoconus, which is considered a traumatic condition. Current dogma states that keratoconus is a multifactorial condition whose mechanisms remain to be elucidated, and eye rubbing is considered as a simple risk factor. This is a major mistake from my point of view and an example of confusion between correlation and cause, although usually confusion occurs in the other direction (correlated factors are confused with causal mechanisms). It is important to reinterpret the medical literature and realize that repeated eye rubbing episodes exerted on the cornea, which precede by months or years the discovery of keratoconus, can inflict tissue trauma that alone can cause the corneal deformation and thinning characteristic of the disease.

News
November 24, 2019
2 min watch
Save

VIDEO: Ocular Therapeutix delivers update on Dextenza launch

VIDEO: Ocular Therapeutix delivers update on Dextenza launch

NEW YORK — At the OSN New York 2019 meeting, Scott Corning, senior vice president of commercial, gives an update on the launch of Dextenza, the dexamethasone-eluting intracanalicular insert indicated for the management of inflammation and pain following ophthalmic surgery.

News
November 16, 2019
8 min read
Save

COLCOT: Low-dose colchicine reduces CV risk after MI

COLCOT: Low-dose colchicine reduces CV risk after MI

PHILADELPHIA — Adults with a recent MI were less likely to experience an ischemic CV event over 2 years when assigned the anti-inflammatory gout medication colchicine compared with assignment to placebo, according to new results of the COLCOT trial presented at the American Heart Association Scientific Sessions.

News
November 15, 2019
2 min read
Save

Site assessment score reduces central venous catheter complications

The implementation of a novel central-line insertion site assessment score reduced the prevalence of lines with local inflammation or infections, ensured timely response to localized symptoms and reduce central line dwell time at a hospital in California, researchers reported.

News
November 10, 2019
2 min read
Save

Methotrexate inhibits progressive joint damage in hand OA, fails to improve pain, function

Methotrexate inhibits progressive joint damage in hand OA, fails to improve pain, function

ATLANTA — Methotrexate significantly reduced the progression of joint damage among patients with erosive hand osteoarthritis, but demonstrated no significant improvement in pain or function over placebo, according to a presentation at the 2019 ACR/ARP Annual Meeting.

News
November 01, 2019
1 min read
Save

Gilead, Glympse partner to assess NASH treatment response in trials

Gilead Sciences announced a strategic collaboration with Glympse Bio for clinical development of nonalcoholic steatohepatitis therapy, according to a press release.

News
November 01, 2019
1 min read
Save

FDA grants fast track designation to FXR agonist for NASH

The FDA granted fast track designation to Terns Pharmaceuticals for TERN-101, an investigational farnesoid X receptor being evaluated for nonalcoholic steatohepatitis, according to a press release.

News
October 22, 2019
2 min read
Save

Protection of erythropoietin and vitamin D production can help preserve kidney output in ESKD

Preservation of residual kidney function reduces morbidity, improves survival and offers other benefits to patients with ESKD. However, more study is needed to understand the mechanisms of residual kidney function along with methods and treatments that can successfully extend preservation, according to a recently published study.

View more